TB-500 Peptide (TB4) 10MG

Thymosin beta-4 (Tβ4), commonly known as TB-500, is a small actin-sequestering molecule that plays a critical role in the cytoskeletal organization of mammalian cells. Unlike growth factors, Tβ4 is not secreted or stored in extracellular matrices but exists within nearly all cells, especially in platelets and white blood cells. This intracellular localization allows rapid mobilization during tissue injury, supporting repair mechanisms from the earliest inflammatory stages. While typical growth factors such as VEGF or EGF measure 14–16 kDa, Tβ4 is much smaller (4.96 kDa), enabling enhanced tissue diffusion and bioavailability. Unlike growth factors that bind to heparin and act on specific receptor types, Tβ4 exerts broad, multifunctional effects including anti-inflammatory, antimicrobial, angiogenic, and anti-apoptotic actions. Its ability to modulate various cellular processes places Tβ4 apart from conventional peptide hormones or cytokines and makes it a prime candidate among synthetic peptides for regenerative properties.

TB-500 studies highlight several biological mechanisms underlying its tissue-healing potential in animals:

• Anti-inflammatory and antimicrobial effects: Tβ4 downregulates cytokines and chemokines, reducing swelling, tissue necrosis, and oxidative damage while preventing bacterial infection at wound sites.
• Promotion of angiogenesis and re-epithelialization: It stimulates endothelial and epithelial cell migration, facilitating new vessel formation and surface restoration, particularly evident in dermal and corneal models.
• Anti-apoptotic and antifibrotic actions: In cardiac and neural injury models, Tβ4 preserves cell viability and reduces fibrotic scarring, maintaining functional tissue architecture.
• Stem cell activation: It promotes progenitor cell migration and differentiation, contributing to cardiac, dermal, and hair follicle regeneration.

Together, these mechanisms establish Tβ4 as a multifunctional synthetic peptide capable of modulating inflammation, cell survival, and structural remodeling.

Extensive TB-500 research demonstrates Tβ4's efficacy when administered topically in ocular and dermal injury models. Corneal Wound Healing In mouse and rat models with alkali burns or heptanol-induced epithelial debridement, topical Tβ4 (5 µg/5 µL twice daily) markedly accelerated corneal re-epithelialization. Treatment reduced inflammation by suppressing TNF-α and NF-κB signaling, decreasing matrix metalloproteinase activity, and increasing laminin-5 production for cell adhesion. Notably, corneal angiogenesis was not induced, maintaining ocular transparency. Dermal Wound Repair In full-thickness punch wounds in mice and rats, Tβ4 (5–50 µg per wound) promoted accelerated closure, collagen deposition, and angiogenesis. Healing improvements were observed even in diabetic, aged, or corticosteroid-suppressed animals, validating its regenerative versatility. Both recombinant and synthetic peptide forms yielded comparable efficacy. Hair Growth Stimulation An unanticipated finding across dermal models was enhanced hair regrowth near Tβ4-treated sites. Topical doses (2.5–5 µg/50 µL hydrogel) in mice and rats stimulated thicker, darker hair via activation of bulge-region stem cells and their differentiation—indicative of follicular renewal rather than neogenesis.

Systemic TB-500 studies span diverse species and injury models, highlighting multi-organ benefits. Cardioprotection In murine coronary ligation and porcine reperfusion models, systemic or intracardiac administration (400 ng to 15 mg per animal) reduced infarct size, improved myocardial function, and enhanced survival. Mechanistically, Tβ4 activated integrin-linked kinase (ILK) and Akt pathways, promoting cardiac cell migration, stem cell differentiation, and angiogenesis, while mitigating fibrosis. Neurological Protection In rats, intracerebroventricular Tβ4 (4.3 µg twice daily for 5 days) prevented hippocampal neuron loss from excitotoxic damage. In multiple sclerosis models, repeated intraperitoneal administration (6 mg/kg) led to functional recovery, reduced inflammation, and increased mature oligodendrocytes, confirming neuroregenerative capacity. Anti-Sepsis Activity In rat endotoxin shock models, Tβ4 administration (100 µg per animal) reduced mortality by downregulating inflammatory cytokines such as TNF-α and IL-1. Observations of naturally decreased circulating Tβ4 during sepsis suggest a protective host-response role that synthetic supplementation may reinforce.

Across species—rats, dogs, and monkeys—high-dose evaluations confirmed an excellent safety profile. Intravenous doses up to 60 mg/kg in rats and dogs and 50 mg/kg in monkeys caused no observable toxic effects, while 250 mg/kg in extended trials remained well tolerated. These results strongly indicate broad systemic tolerance, supporting Tβ4's progression toward human trials.

Animal research on thymosin beta-4 (Tβ4, TB-500) demonstrates that this small, actin-binding synthetic peptide exerts a broad spectrum of regenerative effects across multiple organ systems. Its capacity to modulate inflammation, stimulate angiogenesis, inhibit apoptosis, and activate stem cells distinguishes it from conventional single-target growth factors. In ocular and dermal wound models, Tβ4 accelerated epithelial closure, enhanced collagen deposition, and reduced inflammatory infiltration without inducing unwanted neovascularization. In systemic applications, the peptide provided significant cardioprotection by activating integrin-linked kinase and Akt pathways, promoted neuronal survival and functional recovery in neurological injury models, and reduced mortality in septic shock through cytokine suppression. Equally important, toxicology studies in rats, dogs, and monkeys revealed excellent systemic tolerance, even at doses exceeding 60 mg/kg intravenously, with no observed toxic effects. Overall, the collective TB-500 research supports advancing Tβ4 into clinical translation for dermal, cardiac, ocular, and neurological repair. The consistency of its results across species and injury types strongly indicates that Tβ4 represents a next-generation regenerative peptide capable of bridging preclinical efficacy with future human therapies.